Presurgical irrigation with Povidone-iodine may prevent endometritis after cesarean, finds AJOG study

Published On 2019-10-04 13:58 GMT   |   Update On 2019-10-04 13:58 GMT

Florida: Presurgical vaginal irrigation with povidone-iodine 1% reduced the risk of endometritis, postoperative wound infections, and fever most effectively in women who underwent cesarean delivery, finds a recent study published in the American Journal of Obstetrics & Gynecology.


According to the study, povidone-iodine 1% performed most effectively as a vaginal antiseptic among the other antiseptics used in the study, to prevent post-cesarean endometritis.


Endometritis is the inflammation of endometrium (inner lining of the uterus). It is the most common cause of the infection that can occur up to 6 weeks after childbirth. Its occurrence is much more common after cesarean section births. The condition, although, not life-threatening, but it becomes important to get it treated as soon as possible. Symptoms include fever, lower abdominal pain, and abnormal vaginal bleeding or discharge.


Jared T. Roeckner, Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, and colleague reviewed the literature systematically and quantitated and summarized indirectly the comparative efficacy of antiseptic formulations and their concentrations that are used for the preparation of the vagina before cesarean delivery in the prevention of endometritis and other infectious complications.


The researchers searched for online databases from inception to November 2018. They selected randomized clinical trials of patients who underwent surgical preparation of the vagina with antiseptic formulations before cesarean delivery with the aim of reducing the risk of infectious morbidity.







Direct and indirect pairwise comparisons of the various formulations and their concentrations were performed with the use of multivariate random-effects models and metaregression. A frequentist inference method was employed for the fitted model to estimate the ranking probabilities. Subgroup analyses for patients in labor, not in labor, and with ruptured membranes were conducted.






"For the prevention of endometritis, we identified 23 studies that comprised 7097 women who were allocated to the following treatments: povidone-iodine (1%, 5%, 10%), chlorhexidine (0.2%, 0.4%), metronidazole gel, cetrimide, or normal saline solution/no treatment," wrote the authors.

Also Read: Timing of pushing makes no difference in vaginal delivery: JAMA


Key findings include:

  • Direct and indirect pairwise comparisons indicated that, when compared with saline solution or no treatment, all antiseptic formulations decreased rates of endometritis (5.2% vs 9.1%; 22 studies/6994 women).

  • Individually, povidone-iodine (odds ratio, 0.43;16 studies/5968 women), cetrimide (odds ratio, 0.34; 1 study/200 women), and metronidazole (odds ratio, 0.38; 1 study/224 women) significantly reduced the risk of endometritis.

  • Rankings of vaginal preparations indicated that povidone-iodine 1% had the highest probability (72.7%) of being the most effective treatment for the prevention of endometritis.

  • For the secondary outcomes of postoperative wound infection and fever, a significant reduction was found only with povidone-iodine (odds ratio, 0.61; 16 studies/5968 women; and odds ratio, 0.58; 12 studies/4667 women).

  • Subgroup analyses also found that povidone-iodine significantly reduced risk of endometritis for women in labor (odds ratio, 0.42; studies/1211 women), with ruptured membranes(odds ratio, 0.21; 4 studies/476 women), and undergoing planned cesarean delivery (odds ratio, 0.39; 8 studies/1825 women).


Also Read: Prophylactic antibiotics after assisted childbirth decrease Sepsis risk: Lancet


"Povidone-iodine 1% is the most effective vaginal antiseptic for preventing post-cesarean endometritis," concluded the authors.






To read the complete study log on to https://doi.org/10.1016/j.ajog.2019.04.002


Article Source : With inputs from American Journal of Obstetrics & Gynecology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News